Article Information
History
- July 4, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Dianne Acoba, MSc1,2,
- Anna Levin, MD3,
- Anna Witasp, PhD3,
- Kerstin Ebefors, PhD4,
- Johan Mölne, MD5,
- Peter J. Greasley, PhD6,
- Jenny Nyström, PhD4,
- Annika Wernerson, MD PhD3 and
- Anna Reznichenko, MD PhD1,*
- 1Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- 2Institut Necker Enfants Malades (INEM), Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Université Paris Cité, Paris, France
- 3Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden
- 4Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 5Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 6Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- ↵*Correspondence:
Anna Reznichenko, Clinical Renal, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden, +46 72 515 82 70, Anna.Reznichenko{at}astrazeneca.com
Posted July 04, 2024.
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progression
